Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Atezolizumab

Review the clinical trials studying atezolizumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 104

Atezolizumab with Capecitabine and Oxaliplatin Before Surgery for the Treatment of Resectable Non-Metastatic Proficient Mismatch Repair Colon Cancer, NICER Trial
Status: Active
Location: 2 locations
Atezolizumab with Cisplatin or Carboplatin and Etoposide Followed by Cystectomy for the Treatment of Patients with Localized Small Cell Neuroendocrine Bladder Cancer
Status: Active
Location: 2 locations
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Status: Active
Location: 3 locations
A Study Evaluating Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
Status: Active
Location: 2 locations
Valemetostat and Atezolizumab for the Treatment of Extensive-Stage Small Cell Lung Cancer
Status: Active
Location: 2 locations
Atezolizumab with Stereotactic Body Radiation Therapy and Surgery for the Treatment of Patients with Osteosarcoma with Pulmonary Metastasis
Status: Active
Location: 2 locations
Evaluating Response to Atezolizumab and Bevacizumab Treatment in Patients with Gastrointestinal Cancers and Minimal Residual Disease using ctDNA
Status: Active
Location: MedStar Georgetown University Hospital, Washington, District of Columbia
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Testing Immunotherapy with or without Stereotactic Body Radiation Therapy in Patients with Advanced Liver Cancer, HELIO-RT Trial
Status: Active
Location: Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Vismodegib and Atezolizumab for the Treatment of Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Stereotactic Body Radiation Therapy and Atezolizumab in Treating Patients with Recurrent, Persistent, or Metastatic Cervical, Vaginal, or Vulvar Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Atezolizumab and Tiragolumab for the Treatment of Patients with Refractory Locally Advanced, Metastatic or Recurrent Cancer of Unknown Primary
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Cabozantinib and Atezolizumab for the Treatment of Stage IV Pancreatic Cancer
Status: Active
Location: Banner University Medical Center - Tucson, Tucson, Arizona
Tiragolumab with Carboplatin, Pemetrexed, and Atezolizumab for the Treatment of Non-squamous Non-small Cell Lung Cancer and Untreated Brain Metastases
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults with Recurrent or Metastatic Osteosarcoma, TACOS Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab and Bevacizumab with Y90 Radioembolization for the Preparation for Liver Transplantation for Patients with Hepatocellular Carcinoma
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Lamivudine in Combination with Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Immunotherapy with or without Chemotherapy for the Treatment of Metastatic or Unresectable Non-small Cell Lung Cancer
Status: Active
Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Tiragolumab and Atezolizumab for the Treatment Newly Diagnosed PD-L1 Positive Resectable Stage III-IV Oral Cavity Squamous Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas